Exelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon Follow
Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. See why I ...
The Secret Excel Function That Simplifies Data Like Never Before
Learn how to master Excel's MOD function for smarter data management, advanced analysis, and streamlined workflows in your ...
Exelixis targets $5B Zanza sales by 2033 with multiple pivotal trials in progress
CEO Mike Morrissey highlighted significant momentum in 2024, emphasizing the company's goal of achieving $3 billion in annual cabozantinib (Cabo) revenue by 2030 and $5 billion for zanzalintinib ...
Grasim Industries share price jumps 3% despite posting weak Q3 results 2025. Do you own?
Grasim Industries’ shares were up by 2.77 per cent, reaching an intraday high of ₹2,542 per share in today’s trading. However ...